Allovir, Inc. (ALVR, Financial) has witnessed a notable stock price decline of 5.16%. The stock is currently priced at $0.810 per share, with a trading volume of 63,122 shares and a turnover rate of 0.05%. The stock's amplitude stands at 5.62%.
Recent financial reports reveal concerning figures for Allovir, Inc. The company reported zero revenue and a net loss of $6.08 million, translating to an earnings per share (EPS) of -$0.05. The gross profit remains at $0.00, leading to a price-to-earnings (P/E) ratio of -0.66. Among the three institutions that rated the stock, 67% recommend selling, while 33% suggest holding, with none advising a buy.
In the biotechnology sector, where Allovir operates, there's been a general increase of 0.10%. Other notable performers in the sector include Bright Minds Biosciences Inc., Apollomics Inc., and 60 Degrees Pharmaceuticals Inc., which have shown significant growth. Bright Minds Biosciences Inc., Salarius Pharmaceuticals, Inc., and Lipella Pharmaceuticals Inc. have high turnover rates, while stocks like Psyence Biomedical Ltd and Apollomics Inc. exhibit substantial amplitude.
Allovir is a late-stage clinical cell therapy company specializing in innovative allogeneic T cell therapies for viral diseases. Their proprietary VST therapy platform aims to provide off-the-shelf solutions for patients with limited treatment options, targeting 11 severe viruses. The main candidate, posoleucel, is designed to combat six specific viruses.
